These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 20520303)

  • 1. Noradrenergic adverse effects due to combined treatment with reboxetine and triiodothyronine.
    Cooper-Kazaz R; Cohen A; Lerer B
    J Clin Psychopharmacol; 2010 Apr; 30(2):211-2. PubMed ID: 20520303
    [No Abstract]   [Full Text] [Related]  

  • 2. Urinary retention with reboxetine-fluoxetine combination in a young man.
    Benazzi F
    Can J Psychiatry; 2000 Dec; 45(10):936. PubMed ID: 11190365
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
    Langworth S; Bodlund O; Agren H
    J Clin Psychopharmacol; 2006 Apr; 26(2):121-7. PubMed ID: 16633139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
    Fava M; McGrath PJ; Sheu WP;
    J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reboxetine addition in patients with mirtazapine-resistant depression: a case series.
    López-Muñoz F; Rubio G; Alamo C; García-García P; Pardo A
    Clin Neuropharmacol; 2006; 29(4):192-6. PubMed ID: 16855420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term augmentation with T3 in refractory major depression.
    Kelly TF; Lieberman DZ
    J Affect Disord; 2009 May; 115(1-2):230-3. PubMed ID: 19108898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing reboxetine-associated urinary hesitancy in a patient with major depressive disorder: a case study.
    Kasper S
    Psychopharmacology (Berl); 2002 Feb; 159(4):445-6. PubMed ID: 11823898
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of reboxetine, a selective norepinephrine reuptake inhibitor, on sympathetic and parasympathetic outflow to the heart: preliminary data.
    Agelink MW; Ullrich H; Baumann B; Strum S; Majewski T
    Psychopharmacology (Berl); 2002 Sep; 163(2):151-6. PubMed ID: 12202961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reboxetine and treatment-refractory elderly patients with depression.
    Chue P
    Can J Psychiatry; 2000 Sep; 45(7):669. PubMed ID: 11056834
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of co-administration of lithium and reboxetine on extracellular monoamine concentrations in rats.
    Kitaichi Y; Inoue T; Nakagawa S; Izumi T; Koyama T
    Eur J Pharmacol; 2004 Apr; 489(3):187-91. PubMed ID: 15087241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review.
    Burrows GD; Maguire KP; Norman TR
    J Clin Psychiatry; 1998; 59 Suppl 14():4-7. PubMed ID: 9818623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chemotherapy of melancholia by sequential neuroleptic-viloxazine association].
    Brion S; Chevalier JF; Guerin R; Ginestet D
    Encephale; 1976; 2(3):257-71. PubMed ID: 991806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reboxetine induced erectile dysfunction and spontaneous ejaculation during defecation and micturition.
    Sivrioglu EY; Topaloglu VC; Sarandol A; Akkaya C; Eker SS; Kirli S
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):548-50. PubMed ID: 17123681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sleepwalking associated with reboxetine in a young female patient with major depression--a case report.
    Künzel HE; Schuld A; Pollmächer T
    Pharmacopsychiatry; 2004 Nov; 37(6):307-8. PubMed ID: 15551201
    [No Abstract]   [Full Text] [Related]  

  • 15. Reboxetine: a review of antidepressant tolerability.
    Mucci M
    J Psychopharmacol; 1997; 11(4 Suppl):S33-7. PubMed ID: 9438231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode.
    Pintor L; Baillès E; Valldeoriola F; Tolosa E; Martí MJ; de Pablo J
    Gen Hosp Psychiatry; 2006; 28(1):59-64. PubMed ID: 16377367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
    Akkaya C; Sivrioglu EY; Akgoz S; Eker SS; Kirli S
    Hum Psychopharmacol; 2006 Jul; 21(5):337-45. PubMed ID: 16856215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can nonantidepressants help treat depression?
    Chilakamarri G; Weismantel D; Weismantel A
    J Fam Pract; 2009 Oct; 58(10):550-1. PubMed ID: 19874735
    [No Abstract]   [Full Text] [Related]  

  • 19. Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder.
    Ratner S; Laor N; Bronstein Y; Weizman A; Toren P
    J Am Acad Child Adolesc Psychiatry; 2005 May; 44(5):428-33. PubMed ID: 15843764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of non-SIADH-induced hyponatremia in depression after treatment with reboxetine.
    Koelkebeck K; Domschke K; Zwanzger P; Hetzel G; Lang D; Arolt V
    World J Biol Psychiatry; 2009; 10(4 Pt 2):609-11. PubMed ID: 17965988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.